Index RUT
P/E -
EPS (ttm) -1.46
Insider Own 20.81%
Shs Outstand 105.41M
Perf Week 10.83%
Market Cap 657.76M
Forward P/E -
EPS next Y -1.06
Insider Trans -0.04%
Shs Float 83.48M
Perf Month 34.19%
Income -120.74M
PEG -
EPS next Q -0.23
Inst Own 74.58%
Short Float 6.99%
Perf Quarter 35.95%
Sales 0.00M
P/S -
EPS this Y 44.85%
Inst Trans 10.07%
Short Ratio 1.99
Perf Half Y 35.65%
Book/sh 2.90
P/B 2.15
EPS next Y -8.13%
ROA -42.15%
Short Interest 5.84M
Perf Year 85.16%
Cash/sh 2.51
P/C 2.48
EPS next 5Y 38.60%
ROE -50.60%
52W Range 1.57 - 8.40
Perf YTD 37.44%
Dividend Est. -
P/FCF -
EPS past 5Y -29.69%
ROI -41.50%
52W High -25.71%
Beta 1.24
Dividend TTM -
Quick Ratio 20.62
Sales past 5Y 0.00%
Gross Margin -
52W Low 297.45%
ATR (14) 0.46
Dividend Ex-Date -
Current Ratio 20.62
EPS Y/Y TTM 40.91%
Oper. Margin 0.00%
RSI (14) 62.87
Volatility 7.46% 8.37%
Employees 71
Debt/Eq 0.12
Sales Y/Y TTM -
Profit Margin -
Recom 1.00
Target Price 15.67
Option/Short Yes / Yes
LT Debt/Eq 0.11
EPS Q/Q 60.82%
Payout -
Rel Volume 0.40
Prev Close 6.18
Sales Surprise -
EPS Surprise 38.18%
Sales Q/Q -
Earnings May 13 BMO
Avg Volume 2.94M
Price 6.24
SMA20 15.09%
SMA50 19.02%
SMA200 40.71%
Trades
Volume 1,179,864
Change 1.05%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-01-24 Upgrade
JP Morgan
Neutral → Overweight
$11
Dec-21-23 Upgrade
BofA Securities
Neutral → Buy
$4 → $6
Oct-30-23 Initiated
Wells Fargo
Overweight
$11
May-26-23 Downgrade
BofA Securities
Buy → Neutral
$8 → $3
May-25-23 Downgrade
JP Morgan
Overweight → Neutral
$19 → $9
Sep-16-22 Initiated
Jefferies
Buy
$12
Sep-09-22 Initiated
BTIG Research
Buy
$15
Nov-30-21 Initiated
H.C. Wainwright
Buy
$40
Sep-23-21 Initiated
Cantor Fitzgerald
Overweight
$40
Jan-26-21 Initiated
Needham
Buy
$37
Aug-18-20 Initiated
JP Morgan
Overweight
$33
Aug-18-20 Initiated
Cowen
Outperform
Aug-18-20 Initiated
BofA Securities
Buy
$33
Show Previous Ratings
Jul-16-24 04:05PM
Jul-11-24 06:09PM
(GlobeNewswire) +8.53%
+11.15%
Jun-29-24 08:48PM
Jun-28-24 09:40AM
Jun-27-24 09:55AM
05:00PM
Loading…
Jun-25-24 05:00PM
05:00PM
Jun-24-24 06:35AM
Jun-18-24 08:00AM
Jun-17-24 04:05PM
Jun-07-24 09:40AM
Jun-05-24 11:04PM
(GlobeNewswire) +13.36%
-13.25%
10:57AM
09:55AM
04:45AM
05:06PM
Loading…
Jun-04-24 05:06PM
12:06PM
08:46AM
07:28AM
07:00AM
07:00AM
Jun-03-24 04:30PM
May-20-24 09:35AM
May-16-24 04:05PM
May-13-24 02:53PM
08:00AM
May-09-24 08:00AM
May-07-24 12:30PM
May-01-24 10:15AM
08:00AM
09:35AM
Loading…
Apr-25-24 09:35AM
Apr-17-24 09:40AM
Apr-16-24 04:05PM
09:00AM
Apr-14-24 12:52PM
Apr-10-24 06:15PM
Apr-03-24 08:00AM
Apr-01-24 12:00PM
09:55AM
Mar-28-24 05:31AM
Mar-26-24 08:53PM
04:05PM
Mar-18-24 04:05PM
Mar-14-24 08:40AM
Mar-12-24 02:51PM
Feb-27-24 08:00AM
Feb-21-24 08:00AM
Feb-20-24 04:05PM
Feb-13-24 01:10PM
Jan-18-24 09:40AM
Jan-17-24 11:06AM
Jan-07-24 08:00PM
Dec-27-23 06:30AM
Dec-20-23 05:27PM
05:10PM
05:08PM
Dec-18-23 04:01PM
Nov-22-23 04:01PM
Nov-14-23 07:20PM
Nov-13-23 06:30AM
Nov-09-23 06:30AM
Oct-24-23 06:30AM
Oct-18-23 04:01PM
Oct-10-23 06:30AM
Sep-19-23 06:30AM
Sep-18-23 04:01PM
Sep-08-23 09:35AM
Aug-07-23 06:30AM
Aug-02-23 04:01PM
Jul-30-23 12:00PM
Jul-27-23 06:30AM
Jul-24-23 06:30AM
Jun-14-23 08:36AM
May-30-23 10:40AM
May-26-23 03:05AM
May-25-23 11:52AM
10:12AM
May-24-23 04:01PM
May-16-23 04:01PM
May-08-23 04:01PM
Apr-11-23 06:30AM
Mar-25-23 08:04AM
Mar-06-23 06:30AM
Feb-27-23 06:30AM
Feb-16-23 04:05PM
Feb-12-23 07:35AM
Jan-17-23 04:30PM
Jan-08-23 09:00AM
Jan-06-23 06:30AM
Jan-04-23 06:30AM
Dec-01-22 09:55AM
Nov-21-22 06:13AM
Nov-17-22 04:01PM
Nov-15-22 09:55AM
Nov-03-22 06:30AM
Oct-18-22 04:01PM
Oct-11-22 07:01AM
Sep-16-22 04:01PM
Sep-01-22 05:56PM
(American City Business Journals)
Aug-17-22 04:05PM
Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. It offers drugs that control or target huntington's and alzheimer's disease, multiple sclerosis, glaucoma, parkinson's disease, and spinal muscular atrophy. The company was founded by Ben Barres and Arnon Rosenthal on March 3, 2011 and is headquartered in Brisbane, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Yednock Ted EVP & CHIEF INNOVATION OFFICER Jul 15 '24 Sale 6.02 1,106 6,658 71,365 Jul 17 04:46 PM Lew Jennifer EVP & CHIEF FINANCIAL OFFICER Jul 15 '24 Sale 6.03 1,104 6,657 86,468 Jul 17 04:48 PM Overdorf Michael EVP & CHIEF BUSINESS OFFICER Jul 15 '24 Sale 6.02 784 4,720 94,622 Jul 17 04:49 PM Carson William H. Director Jul 01 '24 Buy 5.00 3,200 16,000 12,800 Jul 02 05:43 PM Carson William H. Director Jun 03 '24 Buy 4.83 3,200 15,459 9,600 Jun 05 04:23 PM Carson William H. Director May 01 '24 Buy 4.68 3,200 14,982 6,400 May 03 04:15 PM Carson William H. Director Apr 08 '24 Buy 6.07 3,200 19,411 3,200 Apr 10 07:17 PM Yednock Ted EVP & CHIEF INNOVATION OFFICER Feb 20 '24 Sale 5.51 2,604 14,348 72,471 Feb 21 04:31 PM Lew Jennifer EVP & CHIEF FINANCIAL OFFICER Feb 20 '24 Sale 5.53 2,593 14,339 82,058 Feb 21 04:31 PM Overdorf Michael EVP & CHIEF BUSINESS OFFICER Feb 20 '24 Sale 5.48 1,951 10,691 85,641 Feb 21 04:31 PM Love Douglas PRESIDENT AND CEO Feb 12 '24 Sale 5.54 5,782 32,032 196,121 Feb 14 07:56 PM Yednock Ted EVP & CHIEF INNOVATION OFFICER Feb 12 '24 Sale 5.54 1,810 10,027 36,075 Feb 14 07:52 PM Lew Jennifer EVP & CHIEF FINANCIAL OFFICER Feb 12 '24 Sale 5.54 1,809 10,022 45,651 Feb 14 07:54 PM Overdorf Michael EVP & CHIEF BUSINESS OFFICER Feb 12 '24 Sale 5.53 1,349 7,460 48,592 Feb 14 07:59 PM Yednock Ted EVP & Chief Innovation Officer Dec 27 '23 Option Exercise 1.63 21,000 34,176 21,000 Dec 29 04:12 PM Yednock Ted EVP & Chief Innovation Officer Dec 27 '23 Sale 4.52 21,000 94,966 0 Dec 29 04:12 PM Satter Muneer A Director Dec 26 '23 Buy 2.88 350,000 1,008,000 7,406,024 Dec 28 04:30 PM
Index -
P/E -
EPS (ttm) -2.57
Insider Own 43.84%
Shs Outstand 27.61M
Perf Week 4.12%
Market Cap 37.28M
Forward P/E -
EPS next Y -0.94
Insider Trans 3.08%
Shs Float 20.73M
Perf Month 10.73%
Income -70.96M
PEG -
EPS next Q -0.23
Inst Own 11.21%
Short Float 0.70%
Perf Quarter 0.00%
Sales 0.00M
P/S -
EPS this Y 49.82%
Inst Trans -4.43%
Short Ratio 0.53
Perf Half Y 57.81%
Book/sh 0.75
P/B 1.35
EPS next Y 32.62%
ROA -73.11%
Short Interest 0.14M
Perf Year -64.18%
Cash/sh 0.92
P/C 1.10
EPS next 5Y -
ROE -128.37%
52W Range 0.49 - 2.94
Perf YTD 83.64%
Dividend Est. -
P/FCF -
EPS past 5Y -44.91%
ROI -211.02%
52W High -65.65%
Beta -0.07
Dividend TTM -
Quick Ratio 2.19
Sales past 5Y 0.00%
Gross Margin -
52W Low 106.12%
ATR (14) 0.07
Dividend Ex-Date -
Current Ratio 2.19
EPS Y/Y TTM 21.31%
Oper. Margin 0.00%
RSI (14) 53.70
Volatility 8.15% 7.22%
Employees 73
Debt/Eq 0.35
Sales Y/Y TTM -
Profit Margin -
Recom 1.50
Target Price 5.50
Option/Short No / Yes
LT Debt/Eq 0.31
EPS Q/Q 25.34%
Payout -
Rel Volume 0.33
Prev Close 0.96
Sales Surprise -100.00%
EPS Surprise -463.64%
Sales Q/Q -
Earnings May 14 BMO
Avg Volume 273.00K
Price 1.01
SMA20 5.49%
SMA50 0.61%
SMA200 -3.16%
Trades
Volume 88,769
Change 5.33%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-21-22 Initiated
Chardan Capital Markets
Buy
$7
Jan-10-22 Initiated
H.C. Wainwright
Buy
$36
Nov-16-21 Initiated
Raymond James
Outperform
$31
Nov-16-21 Initiated
Morgan Stanley
Overweight
$32
Nov-16-21 Initiated
Guggenheim
Buy
$40
Nov-16-21 Initiated
Cowen
Outperform
Jun-13-24 04:05PM
May-29-24 06:05AM
(Pharmaceutical Technology)
May-14-24 01:54PM
07:30AM
Apr-16-24 09:14AM
10:53PM
Loading…
Apr-01-24 10:53PM
04:05PM
Mar-28-24 11:10AM
07:05AM
07:00AM
06:45AM
Feb-28-24 04:01PM
(GlobeNewswire) +5.60%
+7.42%
Jan-31-24 04:01PM
Jan-08-24 07:30AM
Dec-07-23 07:30AM
04:01PM
Loading…
Nov-09-23 04:01PM
(GlobeNewswire) -13.04%
-10.63%
Nov-03-23 12:00PM
Oct-31-23 09:15AM
Sep-27-23 05:02PM
Sep-05-23 08:30AM
07:30AM
Aug-18-23 04:27AM
(Thomson Reuters StreetEvents)
Aug-14-23 07:30AM
Aug-03-23 04:05PM
May-25-23 05:01PM
May-09-23 07:30AM
Apr-03-23 04:05PM
Mar-02-23 04:05PM
Feb-27-23 07:30AM
Feb-16-23 07:30AM
07:30AM
Loading…
Feb-02-23 07:30AM
Jan-26-23 05:30AM
Jan-25-23 09:45AM
Nov-23-22 07:30AM
Nov-09-22 07:30AM
Nov-04-22 07:30AM
Sep-22-22 04:05PM
Sep-15-22 04:05PM
Sep-06-22 04:05PM
Aug-11-22 09:41AM
Aug-09-22 07:30AM
Jun-16-22 07:30AM
May-18-22 07:30AM
May-17-22 07:30AM
May-12-22 07:30AM
Apr-07-22 06:30AM
Mar-01-22 06:30AM
Feb-28-22 06:30AM
Feb-07-22 05:38PM
Feb-03-22 06:30AM
Jan-25-22 10:27AM
Jan-20-22 07:30AM
Jan-06-22 07:30AM
Dec-02-21 07:30AM
Nov-12-21 07:00AM
Oct-27-21 07:45AM
Oct-26-21 04:05PM
Xilio Therapeutics, Inc. operates as a biotechnology company. It focuses on harnessing the immune system to achieve deep and durable clinical responses in cancer. The company uses its proprietary geographically precise solutions platform to rapidly engineer novel molecules, including cytokines and other biologics. Xilio Therapeutics was founded by John C. Williams and Ulrich Rodeck in June 2015 and is headquartered in Waltham, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
GILEAD SCIENCES, INC. 10% Owner Apr 02 '24 Buy 0.76 485,250 368,790 7,345,473 Apr 03 06:50 PM Atlas Venture Fund XI, L.P. 10% Owner Feb 08 '24 Sale 0.64 733 469 2,019,563 Feb 09 04:33 PM Atlas Venture Fund XI, L.P. 10% Owner Feb 08 '24 Sale 0.64 267 171 734,546 Feb 09 04:33 PM Atlas Venture Fund XI, L.P. 10% Owner Jan 12 '24 Sale 0.83 1,540 1,278 2,020,296 Jan 16 06:16 PM Atlas Venture Fund XI, L.P. 10% Owner Jan 12 '24 Sale 0.83 560 465 734,813 Jan 16 06:16 PM Atlas Venture Fund XI, L.P. 10% Owner Jan 11 '24 Sale 0.87 1,566 1,362 2,021,836 Jan 16 06:16 PM Atlas Venture Fund XI, L.P. 10% Owner Jan 11 '24 Sale 0.87 569 495 735,373 Jan 16 06:16 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite